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results from the COMBINE Study
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These analyses of the COMBINE Study examined the effects of naltrexone among non-
abstainers. Given that one of the most well-established mechanisms of action of naltrexone 
involves blunting of alcohol reward, it is hypothesized that naltrexone should be more effective 
among individuals who drank during treatment. Participants were 952 (78% of the total 
COMBINE Study sample) treatment-seeking alcohol-dependent men and women who received 
pharmacotherapy for alcoholism and drank at least once during the 16-week trial. Mixed model 
analyses revealed that individuals who drank more regularly during the trial seemed to benefit 
most from naltrexone and the effects of naltrexone on heavy drinking was significant in treatment 
months 2 through 4 among individuals who reported drinking on 81, 68, and 60% or more of 
days, respectively. Those drinking frequencies were observed in 11, 15, and 19% of the sample. 
Similar effects were not observed for drinks per drinking day. These results suggest that a small 
subgroup of non-abstainers, composed primarily of very regular drinkers, appears to benefit 
from naltrexone in reducing heavy drinking days. Naltrexone may be effective in the context of 
controlled-drinking approaches, even among very frequent drinkers.
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clinically  meaningful effect in decreasing the risk of consistent 
heavy drinking and increasing the likelihood of abstinence from 
alcohol in those studies (Gueorguieva et al., 2007).
In addition to determining the efficacy of naltrexone for the 
treatment of alcoholism, research has focused on understand-
ing the biobehavioral mechanisms and moderators of response 
to naltrexone. To that end, human laboratory studies revealed 
that naltrexone dampens alcohol’s positively reinforcing effects 
(Swift et al., 1994; McCaul et al., 2001; Drobes et al., 2004; Ray 
and Hutchison, 2007), attenuates alcohol craving (O’Malley et al., 
2002; Ray and Hutchison, 2007; Tidey et al., 2008), reduces alco-
hol self- administration (O’Malley et al., 2002; Anton et al., 2004), 
decreases ratings of liking of the alcohol (McCaul et al., 2000; Ray 
and Hutchison, 2007), increases alcohol-induced feelings of fatigue, 
tension, and confusion (King et al., 1997), reduces alcohol con-
sumption and slows down the progression of drinking in a delayed 
access laboratory paradigm (Anton et al., 2004). In short, these 
results suggest that one of the primary biobehavioral mechanisms 
of action of naltrexone involves the reduction of alcohol-induced 
reward, which by definition, presumes alcohol consumption by 
patients while treated with naltrexone.
Studies of the neurobiological effects of naltrexone revealed that 
it occupies opioid receptors preventing the binding of such recep-
tors by endogenous opioid peptides released upon alcohol intake. 
This in turn prevents the γ-aminobutyric acid (GABA)-mediated 
release of dopamine in the ventral tegmental areas thereby puta-
tively blocking alcohol’s reinforcing effects (Anton et al., 1995; Koob 
and Le Moal, 2008). A neuroimaging study found that naltrexone 
reduces alcohol-mediated dopamine output in the ventral stria-
tum (Myrick et al., 2008). Opioid peptides may also play a role in 
IntroductIon
Naltrexone is an opioid receptor antagonist with empirically 
supported efficacy for the treatment of alcoholism when used 
in combination with behavioral treatments (e.g., O’Malley 
et al., 1992; Volpicelli et al., 1992; Anton et al., 1999, 2006; 
Monti et al., 2001). Shortly after two initial trials suggested that 
naltrexone resulted in significantly fewer drinking days and 
lower rates of relapse after 3 months of treatment (O’Malley 
et al., 1992; Volpicelli et al., 1992), naltrexone was advanced as 
one of the more promising pharmacological interventions for 
alcohol dependence (Litten et al., 1996). These initial results 
have been largely supported by more recent trials of naltrexone 
that generally demonstrate beneficial effects on heavy drinking 
rates (Anton et al., 1999; Chick et al., 2000; Monti et al., 2001; 
Morris et al., 2001).
Clinical trials have found that naltrexone reduces the occur-
rence of heavy drinking days (Monti et al., 2001; Rubio et al., 
2002; Balldin et al., 2003), increases time to first relapse (Anton 
et al., 1999; Guardia et al., 2002; Kiefer et al., 2003), yields lower 
relapse rates (Volpicelli et al., 1992; Heinala et al., 2001; Latt et al., 
2002), reduces the number of drinking days (O’Malley et al., 1992; 
Volpicelli et al., 1992), the number of drinks per drinking epi-
sode (O’Malley et al., 1992; Chick et al., 2000; Morris et al., 2001; 
Guardia et al., 2002), and the latency to first and second drink 
among social drinkers (Davidson et al., 1996). However, the sup-
port for naltrexone is not uniform. A few trials, including a large 
multi-site trial, have reported no significant outcome differences 
between naltrexone and placebo-treated patients (Kranzler et al., 
2000; Krystal et al., 2001). Recent trajectory-based re-analyses of 
two negative clinical trials suggested that naltrexone may have a 
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1383 participants were recruited at 11 U.S. sites, all of whom were 
 outpatients who met criteria for alcohol dependence and who 
had been drinking heavily for the 90-day period preceding study 
enrollment (i.e., at least two heavy drinking days – defined as four 
drinks per day for women and five drinks per day for men, during 
a consecutive 30-day period within the 90 days prior to baseline 
evaluation). Exclusion criteria were any serious mental illness or 
unstable medical condition, current dependence on any drug other 
than alcohol, nicotine, or marijuana, taking or requiring any medi-
cation that interfered with the study medications, including any 
significant current opioid use.
Participants were randomly assigned to one of nine treat-
ment conditions and received 16 weeks of active treatment. Eight 
of these groups (n = 1226) received MM plus a combination of 
either active/placebo naltrexone and active/placebo acamprosate. 
These four medication groups were then further divided by two 
levels of behavioral counseling (i.e., CBI vs. no CBI). A ninth group 
(n = 157) received CBI alone, without MM or pills and will not 
be included in the analyses presented herein given the focus on 
naltrexone response. Naltrexone dose in the COMBINE trial was 
100 mg/day (after a 7-day titration up). The primary outcomes for 
the trial were percent days abstinent and time to first heavy drinking 
day, operationalized as five or more drinks in a day for men and 
four or more drinks in a day for women.
data analytIc Strategy
Outcome variables and covariates were culled from the COMBINE 
database. The Form 90 (Miller and Del Boca, 1994; Tonigan et al., 
1997) was the primary measure of drinking outcomes. This 
instrument was administered at 4-week intervals over the course 
of 16 weeks. Consistent with the study hypotheses, the outcome 
variables for these analyses were: (a) PHDD and (b) DPDD. In 
theses analyses, we excluded individuals who remained abstinent 
during the 16-week trial (n = 274, 22%), leaving a total of 952 
participants who drank at least once during the trial. In order to 
examine the effects of naltrexone on PHDD and DPDD, a series 
of repeated measures mixed model analyses were conducted using 
PROC MIXED in SAS Statistical Software. Grouping of the medica-
tion and psychosocial treatment conditions were identical to those 
in the Analyses of Variance (ANOVAs) conducted for the main trial 
(Anton et al., 2006).
Consistent with the approach of the primary analyses of the 
COMBINE Study (Anton et al., 2006) the effects of naltrexone were 
examined across levels of behavioral counseling and acamprosate, 
in order to maximize statistical power. Given that the present study 
focuses on the effects of naltrexone among non-abstainers, levels of 
counseling were not added to the statistical models. In these analy-
ses, each dependent variable (PHDD and DPDD) was modeled as 
a function of time (linear and quadratic effects of month, initially 
centered at the 1-month assessment), naltrexone (0 = no, 1 = yes), 
and percent drinking days (PDD, modeled with both linear and 
quadratic effects), and their interactions. The interaction between 
PDD, a time varying covariate capturing drinking frequency, and 
naltrexone allowed us to test whether the efficacy of naltrexone 
vs. no-naltrexone on drinking outcomes differed as a function of 
drinking levels over the course of treatment. The intercept and 
time trends were allowed to vary randomly across individuals. 
 alcohol and drug reward through non-dopamine mediated path-
ways (Koob, 1992). Opioid blockade, tested mostly using naloxone, 
has been found to increase blood levels of adrenocorticotropic hor-
mone (ACTH), beta-endorphin, and cortisol in humans (Naber 
et al., 1981; Schluger et al., 1998). Nevertheless, null findings have 
also been reported (Kemper et al., 1990). These findings suggest a 
potential role of the hypothalamo-pituitary-adrenocortical (HPA) 
axis activity in mediating the neurobiological effects of naltrexone, 
a finding that is supported by recent human laboratory studies (e.g., 
O’Malley et al., 2002; Ray et al., 2009). As with the biobehavioral 
mechanisms reviewed above, the putative neurobiological mecha-
nisms of naltrexone involve the blunting of alcohol-induced reward 
through both opioid and dopamine mediated pathways.
The COMBINE Study was a large multi-site 16-week alco-
hol dependence treatment study (see Materials and Methods for 
details). The main results from the COMBINE Study indicated 
that naltrexone was superior to no-naltrexone on a number of 
drinking outcome variables. The effects of naltrexone were in large 
part observable only when behavioral counseling (i.e., Combined 
Behavioral Intervention, CBI) was not used concomitantly with 
naltrexone and Medical Management (MM). Details on the main 
results of the COMBINE study have been described in Anton et al. 
(2006). In light of the literature on the biobehavioral and neurobio-
logical mechanisms of action of naltrexone, these secondary analy-
ses of the COMBINE Study (2003a,b) seek to examine the effects 
of naltrexone among individuals who drank during the course of 
the 16-week treatment. Given that one of the most well-established 
mechanisms of action of naltrexone involves blunting of alcohol 
reward, it is hypothesized that naltrexone should be effective among 
individuals who drank during the COMBINE trial.
Specifically, we hypothesize that the degree to which patients 
drink during the trial may moderate the efficacy of naltrexone, as 
measured by the following outcomes: (a) percent heavy drinking 
days (PHDD) and (b) drinks per drinking day (DPDD). This is con-
sistent with the recognition that, at least some, of the well- established 
mechanisms of action of naltrexone presuppose alcohol consump-
tion. Alcohol is thought to interact with the pharmacological effects 
of naltrexone resulting in decreased reinforcing effects from alco-
hol and ultimately, reduced alcohol intake within a drinking epi-
sode (Pettinati et al., 2006). An examination of outcomes among 
individuals who drank during treatment in the COMBINE Study 
(i.e., non-abstainers) and of the frequency with which they drank 
is consistent with the putative mechanisms of naltrexone action 
that involve changes in subjective intoxication. These biobehavioral 
mechanisms, in turn, are often captured in human laboratory studies 
and these analyses will bridge the human behavioral pharmacology 
and clinical treatment approaches. These analyses will also provide 
clinically useful information on treatment non-abstainers, including 
their response to naltrexone and how drinking frequency influences 
drinking outcomes and naltrexone response.
MaterIalS and MethodS
SuMMary of the coMBIne Study
The rationale and methods of the COMBINE Study (2003a,b) 
have been described in detail elsewhere. In brief, COMBINE was 
designed to test the outcome of different levels of pharmacother-
apy and psychotherapy interventions for alcoholism. A total of 
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Non-significant interactions were trimmed from the final models 
reported below. All analyses controlled for pre-treatment levels of 
the relevant dependent measure. Lastly, a Bonferroni correction was 
implemented and since two dependent variables were analyzed in 
this study, the adjusted critical p-value was set at 0.025. This is the 
same a priori adjusted p-value used in the COMBINE Study main 
analyses (Anton et al., 2006).
reSultS
Correlational analyses examined the associations between the three 
measures of drinking used in this study: (a) PDD; (b) PHDD; and 
(c) DPDD. Across the 4 months of active treatment, the associa-
tion between PDD and DPDD ranged between r = 0.08 and 0.18. 
The association between PDD and PHDD ranged between r = 0.78 
and 0.81. And the correlation between DPDD and PHDD ranged 
between r = 0.42 and 0.49. The following analyses address the pri-
mary study objectives.
Percent heavy drInkIng dayS
As shown in Table 1, mixed model analyses revealed a number 
of significant higher-order interactions, including a significant 
Month × drinking frequency (PDD) × Naltrexone interaction 
[B = −0.03, SE = 0.01, t(2731) = −2.86, p < 0.01] and a significant 
quadratic PDD × Naltrexone interaction [B = −0.002, SE = 0.0005, 
t(2731) = −3.75, p < 0.01]. This indicates a complex pattern in 
the benefit of Naltrexone treatment for individuals with varying 
frequency of alcohol use over time (see Figure 1). There was no 
significant difference between naltrexone and no-naltrexone at 
month 1. Successively re-centering the time and PDD variables and 
rerunning the analyses allowed us to determine which individuals 
(as a function of their drinking pattern) experienced a benefit from 
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FIgurE 1 | Percent heavy drinking days (PHDD) as a function of percent 
drinking days (PDD) for individuals treated with naltrexone (NTX) vs. 
no-naltrexone across treatment months.
naltrexone during the later course of treatment. Specifically, there 
was no significant difference between naltrexone and no-naltrexone 
treatment on PHDD, across levels of drinking frequency (PDD) 
Table 1 | Parameter estimates and standard errors from trimmed 
multilevel growth models of percent heavy drinking days (PHDD) and 
drinks per drinking day (DPDD) outcome variables.
Variable PHDD DPDD
 Parameter Standard Parameter Standard 
 estimate error estimate error
Intercept −4.48** 1.39 1.36*** 0.37
NTX −2.41† 1.25 −0.43 0.27
NTX × month 0.37 0.48 – –
PDD 0.49*** 0.04 0.06*** 0.01
PDD × month 0.05* 0.02 −0.01† 0.007
PDD × month × month −0.02*** 0.01 – –
PDD × PDD 0.002*** 0.001 −0.0004** 0.0001
PDD × PDD × month 0.001* 0.0002 0.0002† 0.00007
NTX × PDD 0.19*** 0.05 0.006 0.006
NTX ×  PDD × month −0.03** 0.01 – –
NTX × PDD × PDD −0.002*** 0.001 – –
Month −0.81 0.68 0.69*** 0.19
Month × month 0.26 0.20 −0.17*** 0.05
Baseline measure 0.07*** 0.02 0.37*** 0.02
†p < 0.10, *p < 0.025, **p < 0.01, ***p < 0.001.
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suggesting a small effect size of naltrexone for alcoholism treatment 
and arguing that naltrexone may be most useful in the context 
of controlled drinking (Bouza et al., 2004).These findings may 
also be interpreted in light of studies suggesting that naltrexone 
may be most effective among patients with low levels of alcohol 
dependence severity (Morley et al., 2006). To the extent to which 
individuals who drank during treatment in the COMBINE study 
had lower levels of alcohol dependence severity and were more 
prone to a controlled-drinking treatment goal, it is possible that 
alcoholism severity may help explain these findings. This is con-
sistent with the observation that a low severity of alcohol depend-
ence in the COMBINE sample may explain, at least partially, some 
divergent results between trials in Europe and the US (e.g., alcohol 
dependence score of 38.6 in a recent German trial vs. 16.6 in the 
US COMBINE trial) (Mann et al., 2007).
Interestingly, the significant reduction over time in the per-
centage of drinking days per month required to observe an effect 
of naltrexone on heavy drinking may be seen as consistent with 
the learning theory of addiction, suggesting that repeated experi-
ence of alcohol use at lower levels of reinforcement, putatively 
due to naltrexone’s effects, may be required to modify drink-
ing behavior (i.e., produce reductions in PHDD). The lack 
of significant effects at the first month of treatment may also 
be interpreted from the perspective of a “grace period” in the 
trial, during which the full potential of a treatment is not yet 
observable. Although we did not use a “grace period” approach 
in these analyses, FDA recommendations suggest that a grace 
period may be used in a trial to allow the medication to reach 
therapeutic levels, and importantly, to allow patients to adjust 
to the medication regimen and begin to control their drinking 
with the behavioral and pharmacological tools (FDA, 2006). 
Although the current study was not aimed at identifying the 
optimal therapeutic window for naltrexone, these findings may 
have important clinical implications. Specifically, these results 
suggest that patients who drinking regularly should be encour-
aged to use naltrexone for at least 1 month before medication 
gains can be objectively evaluated.
These results are generally consistent with the clinical observa-
tion and previous empirical studies suggesting that naltrexone may 
work, in part, by preventing drinking episodes from becoming a 
full-fledge relapse into heavy drinking (Anton et al., 1999, 2004; 
O’Malley and Froehlich, 2003; Pettinati et al., 2006). The present 
study addresses the relationship between naltrexone and drinking 
outcomes thought to result from naltrexone-induced blunting of 
alcohol reinforcement, which by definition involves alcohol use by 
naltrexone-treated patients. Conversely, this study does not address 
the effects of naltrexone in promoting abstinence, which has also 
been reported in the literature (Volpicelli et al., 1992; Heinala et al., 
2001; Latt et al., 2002). Naltrexone’s effects on abstinence rates, in 
turn, may be attributed to alternative mechanisms of action of this 
pharmacotherapy, such as reductions in alcohol craving (Anton 
et al., 1999; Monti et al., 2001; Tidey et al., 2008) and improvements 
in response inhibition and more generally, in executive function 
(Crews and Boettiger, 2009).
These results presented herein should be interpreted in the con-
text of the study’s strengths and limitations. Strengths include the 
large and well-characterized sample as well as the  methodological 
at month 1. At month 2, however, naltrexone became statistically 
superior to no-naltrexone in reducing heavy drinking days among 
individuals who reported 80% or more drinking days, which in turn 
represents 11% of participants in these analyses. At month 3, nal-
trexone significantly reduced PHDD among individuals who drank 
on approximately two-thirds of days or more (i.e., ≥68% drinking 
days), which represents 15% of the participants in these analyses. 
And finally, at month 4, naltrexone was superior to no-naltrexone 
in reducing PHDD among individuals who reported 60% or more 
drinking days, which was the case for 19% of the sample. This 
pattern indicates that over time, the effects of naltrexone became 
significant at lower drinking frequency.
In summary, the effects of naltrexone on PHDD among non-
abstainers were moderated by drinking frequency, such that higher 
frequency of drinking was associated with greater benefit from nal-
trexone, as compared to no-naltrexone. The benefits of naltrexone 
were not significant at treatment month 1, but became statistically 
significant at different levels of drinking frequency across treatment 
months 2, 3, and 4. These findings suggest that a small subgroup of 
non-abstainers (11–19% of the sample) benefits from naltrexone 
in reducing heavy drinking days.
drInkS Per drInkIng day
Mixed model analysis revealed no significant drinking fre-
quency (PDD) × naltrexone interaction [B = 0.005, SE = 0.006, 
t(2043) = 0.89, p = 0.37] with regard to DPDD. Moreover, there were 
no significant higher-order interactions involving this effect.
dIScuSSIon
This study examined the clinical effects of naltrexone among indi-
viduals who drank over the course of treatment in the COMBINE 
Study. Given the putative mechanisms of action of this pharma-
cotherapy, namely its reduction of alcohol “high” (Swift et al., 
1994; Volpicelli et al., 1995), it was hypothesized that the degree to 
which patients drink during the trial would moderate the efficacy 
of naltrexone. Specifically, it was argued that regular drinking in 
the presence of active naltrexone treatment would lead to clinical 
benefits, such as reductions in heavy drinking days and DPDD 
via naltrexone-induced alteration of the neuropharmacological 
effects of alcohol. Results of these analyses, excluding all abstain-
ers from the COMBINE Study, provided partial support for these 
hypotheses such that naltrexone interacted with PDD in predicting 
PHDD following the grace period of 1 month (i.e., re-centering the 
treatment variable). Among non-abstainers, which represents the 
vast majority (78%) of patients in the COMBINE Study, individu-
als who drank more regularly during the trial seemed to benefit 
most from naltrexone and the difference between naltrexone and 
non-naltrexone on PHDD was significant in treatment months 
2 through 4 among individuals who drank on 81, 68, and 60% 
or more of days. Similar effects, however, were not observed for 
DPDD. Taken together, these results are somewhat consistent with 
the putative mechanism of action of naltrexone and suggest that 
naltrexone’s beneficial effects among non-abstainers may depend 
on frequency of drinking.
Importantly, the percentage of non-abstainers found to benefit 
from naltrexone in reducing heavy drinking was at best 20%. Albeit 
small, these numbers are consistent with meta-analytic findings 
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